Sledge GW, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy. J Clin Oncol. 2017;35 (suppl; abstr 1000).
Neoadjuvant dostarlimab bij mismatch repair-deficiënte tumoren
jul 2025 | Gynaecologische oncologie, Immuuntherapie, Maag-darm-leveroncologie, Uro-oncologie